JP2017532288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532288A5 JP2017532288A5 JP2017500891A JP2017500891A JP2017532288A5 JP 2017532288 A5 JP2017532288 A5 JP 2017532288A5 JP 2017500891 A JP2017500891 A JP 2017500891A JP 2017500891 A JP2017500891 A JP 2017500891A JP 2017532288 A5 JP2017532288 A5 JP 2017532288A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tau
- disease
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013498 tau Proteins Human genes 0.000 claims description 33
- 108010026424 tau Proteins Proteins 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 208000017004 dementia pugilistica Diseases 0.000 claims description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 3
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000002308 calcification Effects 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 230000002739 subcortical effect Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021897P | 2014-07-08 | 2014-07-08 | |
| US62/021,897 | 2014-07-08 | ||
| PCT/US2015/039205 WO2016007414A1 (en) | 2014-07-08 | 2015-07-06 | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532288A JP2017532288A (ja) | 2017-11-02 |
| JP2017532288A5 true JP2017532288A5 (enExample) | 2018-08-16 |
| JP6913018B2 JP6913018B2 (ja) | 2021-08-04 |
Family
ID=55064732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500891A Active JP6913018B2 (ja) | 2014-07-08 | 2015-07-06 | タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10132818B2 (enExample) |
| EP (1) | EP3166688B1 (enExample) |
| JP (1) | JP6913018B2 (enExample) |
| CN (1) | CN107073297B (enExample) |
| ES (1) | ES2985805T3 (enExample) |
| WO (1) | WO2016007414A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| FI3334761T3 (fi) | 2015-08-13 | 2023-08-14 | Univ New York | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa |
| JP6913078B2 (ja) | 2015-08-13 | 2021-08-04 | ニューヨーク・ユニバーシティ | タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用 |
| RU2760875C1 (ru) | 2016-07-12 | 2021-12-01 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| EP3509622A4 (en) | 2016-09-08 | 2020-06-17 | Regenerative Research Foundation | BI-FUNCTIONAL ANTI-TAU POLYPEPTIDES AND THEIR USE |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3565836A1 (en) | 2017-01-04 | 2019-11-13 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
| KR20190134997A (ko) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | 항-tau 항체 및 이의 사용 방법 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| CN109406469B (zh) * | 2018-10-24 | 2021-04-09 | 中国医科大学 | 基于蛋白结合诱导dna双链变构的检测色氨酸的方法 |
| WO2020123492A1 (en) * | 2018-12-10 | 2020-06-18 | New York University | Monoclonal antibodies targeting c-terminal region of phosphorylated tau |
| JP7702381B2 (ja) * | 2019-07-08 | 2025-07-03 | アルゼカ バイオサイエンシズ、エルエルシー | タウ病理のためのターゲティングリガンド |
| AU2020353719A1 (en) * | 2019-09-23 | 2022-03-10 | Celosia Therapeutics Pty Ltd | Treatment of tauopathies |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US6136548A (en) | 1994-11-22 | 2000-10-24 | Rutgers, The State University Of New Jersey | Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DE69738868D1 (de) | 1996-05-22 | 2008-09-11 | Viventia Biotech Inc | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
| AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2427014A1 (en) | 2000-11-02 | 2002-08-22 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| US6821504B2 (en) | 2001-05-23 | 2004-11-23 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| BRPI0610093A2 (pt) | 2005-05-05 | 2008-12-09 | Merck & Co Inc | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| SI2408807T1 (sl) | 2009-03-18 | 2021-11-30 | Ac Immune Sa | Postopek za terapevtsko uporabo |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP4218794A3 (en) * | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| JP6358953B2 (ja) * | 2011-10-07 | 2018-07-18 | エーシー イミューン エス．エー． | タウを認識するホスホ特異的抗体 |
-
2015
- 2015-07-06 US US15/324,141 patent/US10132818B2/en active Active
- 2015-07-06 JP JP2017500891A patent/JP6913018B2/ja active Active
- 2015-07-06 CN CN201580047108.9A patent/CN107073297B/zh active Active
- 2015-07-06 EP EP15818480.4A patent/EP3166688B1/en active Active
- 2015-07-06 ES ES15818480T patent/ES2985805T3/es active Active
- 2015-07-06 WO PCT/US2015/039205 patent/WO2016007414A1/en not_active Ceased
-
2018
- 2018-10-04 US US16/151,555 patent/US10859582B2/en active Active
-
2020
- 2020-10-19 US US17/073,871 patent/US11519920B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532288A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| Toledo et al. | Dementia with Lewy bodies: impact of co‐pathologies and implications for clinical trial design | |
| JP2014503178A5 (enExample) | ||
| Gao et al. | Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease | |
| JP2018534236A5 (enExample) | ||
| US9650436B2 (en) | Antibody based reagents that specifically recognize toxic oligomeric forms of tau | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| JP2014506244A5 (enExample) | ||
| IL310464A (en) | Anti-phf-tau antibodies and uses thereof | |
| JP2015505665A5 (enExample) | ||
| JP2017504570A5 (enExample) | ||
| JP2012530055A5 (enExample) | ||
| US10191068B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| JP7558574B2 (ja) | マルチプレックスアッセイおよびその使用方法 | |
| WO2020106598A1 (en) | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies | |
| Yu et al. | Diagnostic utility of VEGF and soluble CD40L levels in serum of Alzheimer's patients | |
| US20220221795A1 (en) | Methods for detecting traumatic brain injury | |
| AU2020345110A1 (en) | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment | |
| US20140242100A1 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
| JP2015520608A5 (enExample) | ||
| US20200278358A1 (en) | Method of distinguishing between different neurodegenerative diseases | |
| CN108387738B (zh) | 利用蛋白质聚集物的解离来诊断与异常蛋白质聚集或错误折叠相关之疾病的诊断试剂盒 | |
| JP2015522562A5 (enExample) | ||
| Ritchie et al. | Mild cognitive impairment (MCI) twenty years on |